A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Li Zhou,Yanjuan Xiong,Yang Wang,Yuan Meng,Weihong Zhang,Meng Shen,Xinwei Zhang,Shuzhan Li,Baozhu Ren,Runmei Li,Ying Han,Jiali Zhang,Shui Cao,Weijiao Du,Qian Sun,Feng Wei,Xiumei An,Lili Yang,Yuwei Zhang,Wenchao Ma,Wengui Xu,Yi Zhang,Jingting Jiang,Xiang Xu,Jianchuan Xia,Liang Liu,Xiubao Ren
DOI: https://doi.org/10.1016/j.cllc.2022.07.009
IF: 4.84
2022-01-01
Clinical Lung Cancer
Abstract:Introduction: Can the Cytokine-induced killer (CIK) cells in combination with immune checkpoint inhibitor further improve the efficacy of chemotherapy in non-small cell lung cancer (NSCLC) patients? What are the adverse reactions of this combination therapy? But these problems are not clear. Therefore, we conducted a phase 1b trial to evaluate the safety and efficacy of autologous CIK cells therapy combined with Sintilimab, antibody against programmed cell death -1, plus chemotherapy in untreated, advanced NSCLC patients. Patients and Methods: Patients with stage IIIB/IIIC/IV NSCLC received Sintilimab, platinum-based doublet chemotherapy, and CIK cells every 3 weeks for 4 cycles, then maintenance treatment with Sintilimab in squamous and with Sintilimab plus pemetrexed in non-squamous NSCLC until disease progression or unacceptable toxicity or 2 years. The primary endpoints were safety and objective response rate (ORR). Results: Thirty-four patients received the treatment. 94.1% of patients experienced treatment-related adverse events (TRAEs). Grade 3 or greater TRAEs occurred in 64.7% of patients. One (2.9%) patient died of grade 5 immune -related pneumonia. The ORR and DCR were 82.4% (95% CI, 65.5%-93.2%) and 100.0% (95% CI, 89.7%-100.0%), respectively. Objective responses were evaluated in 14 of 15 non-squamous patients (93.3%; 95% CI, 68.1%-99.8%) and in 14 of 19 squamous patients (73.7%; 95% CI, 48.8%-90.9%). Median PFS was 19.3 months (95% CI, 8.3 months to not available). Conclusion: Autologous CIK cells immunotherapy in combination with Sintilimab plus chemotherapy was well tolerable and showed encouraging efficacy in patients with previously untreated, advanced NSCLC (Clinical-Trials.gov number, NCT03987867). Clinical Lung Cancer, Vol. 23, No. 8, 709-719 (c) 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )